Voices
Discussing the Broader Opportunity to Expand Patient Access to Cell Therapies – Legend Biotech
Legend Biotech / LinkedIn

Discussing the Broader Opportunity to Expand Patient Access to Cell Therapies – Legend Biotech

Legend Biotech shared a post on LinkedIn:

“In a recent interview with OncoDaily at European Hematology Association (EHA) 2026, our CEO, Ying Huang, discusses the potential of in vivo CAR-T approaches, the early clinical data from LB2501, and the broader opportunity to expand patient access to cell therapies.”

Watch the full interview here

Legend Biotech

Other articles about Legend Biotech on OncoDaily.

cancer EHA European Hematology Association Legend Biotech OncoDaily Oncology Ying Huang